Foamix Pharmaceuticals Ltd. (FOMX) Shares Up 3%
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) shot up 3% during trading on Tuesday . The stock traded as high as $8.24 and last traded at $8.13, with a volume of 58,712 shares. The stock had previously closed at $7.89.
Several brokerages have commented on FOMX. Zacks Investment Research cut shares of Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. TheStreet raised shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. Finally, Guggenheim reissued a “buy” rating and set a $10.00 price target on shares of Foamix Pharmaceuticals in a research report on Tuesday, May 10th.
The stock’s 50 day moving average price is $7.01 and its 200 day moving average price is $6.59. The stock’s market cap is $249.55 million.
Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.08. Equities analysts predict that Foamix Pharmaceuticals Ltd. will post ($0.89) earnings per share for the current year.
Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.